TERSeptember 21, 2026 at 6:00 AM UTCSemiconductors & Semiconductor Equipment

Teradyne Introduces Iris 100, Extending Test Portfolio to Optical Interconnects

Read source article

What happened

Teradyne announced the Iris 100, a production-ready test system for microLED devices used in optical data interconnects within AI data centers. The new platform extends the company's test portfolio beyond traditional semiconductor and memory test into photonic interconnect testing, aligning with its 'wafer to AI data center' strategy. This follows the earlier MLTP investment, showing continued capital deployment into adjacent AI test markets. The press release does not disclose revenue projections or named customers, and microLED interconnect test is a nascent market, so near-term financial impact is likely modest. The announcement reinforces the long-term growth narrative but does not address the stretched valuation or near-term demand timing concerns highlighted in the master report.

Implication

Investors should view this as a positive signal of management executing on adjacent AI test opportunities, but it is not enough to overcome stretched valuation and concentrated customer risk. Near-term focus remains on Q3 results and memory revenue staying above $200 million. If Iris 100 gains traction with major optical interconnect suppliers, it could expand TAM and diversify revenue, but adoption is unproven and likely several quarters away. Given the stock's rich multiple, we maintain WAIT and prefer entry below $315. Any positive impact from this announcement may already be partially priced given the market's enthusiasm for AI test names.

Thesis delta

The thesis is modestly strengthened by evidence that Teradyne is expanding into adjacent high-growth AI test markets (microLED optical interconnects), consistent with management's 'wafer to AI data center' focus. However, this does not alter the core investment case: near-term demand timing and margin durability remain the key swing factors, and current valuation still leaves no margin of safety. We maintain WAIT with unchanged price targets and monitoring points.

Confidence

medium